Cell therapy (NK cells) · Kills target cells, directed at CD19 · developed by Century Therapeutics
CNTY-101 is an allogeneic natural killer cell preparation derived from a clonal induced pluripotent stem cell line and engineered to express an anti-CD19 chimeric antigen receptor and IL-15. The cells recognize and kill CD19-expressing cells and carry an EGFR-based safety switch that allows their elimination with anti-EGFR antibodies such as cetuximab. It is being studied in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies and diffuse cutaneous systemic sclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06255028 | Phase 1 | Systemic Lupus Erythematosus | Active not recruiting | IPSC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Cutaneous Systemic SclerosisIdiopathic Inflammatory MyopathiesLupus NephritisSystemic Lupus Erythematosus
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPSC page.
See IPSC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPSC catalysts and pipeline →